To outline the role of m6A RNA methylation in immune cell function and autoimmune disease progression, focusing on its regulatory mechanisms.
Approach:
m6A Regulation Overview: The review discusses the m6A regulatory complex, including writers (METTL3/14), erasers (FTO, ALKBH5), and readers (YTHDF1–3, IGF2BP3), and their roles in immune responses.
Disease-Specific Analysis: It provides a comparative analysis of m6A dysregulation across systemic autoimmune diseases (e.g., SLE, RA, psoriasis) and organ-specific diseases (e.g., MS, IBD, T1DM, AITD).
Therapeutic Strategies: Emerging therapies targeting m6A regulators are evaluated, including METTL3 inhibitors (STM2457), ALKBH5 modulation (ALK-04), and FTO-targeting small molecules (Rhein).
Key Findings:
m6A RNA methylation is a crucial post-transcriptional regulator of immune cell function.
Dysregulated m6A signaling is implicated in the pathogenesis of various autoimmune diseases.
Therapeutic targeting of m6A regulators shows promise, but challenges such as stage-specific effects and safety concerns remain.
Interpretation:
The review discusses the complex role of m6A in immune regulation and its potential as a therapeutic target in autoimmune diseases.
Limitations:
Challenges in targeting specific immune subsets.
Concerns regarding the long-term safety of epitranscriptomic drugs.
Further studies are needed to clarify m6A dynamics in immune interactions.
Conclusion:
Future research should explore the interplay between m6A regulation and existing therapies to enhance precision medicine.
